Effects of Rock Climbing on Parkinson's Disease

Sponsor
Marymount University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05919771
Collaborator
(none)
50
1
11
4.5

Study Details

Study Description

Brief Summary

This research study is being conducted to understand the outcomes of participation in the Up ENDing Parkinson's rock climbing program (24 sessions, or twice per week for about 12 weeks) on walking & mobility, hand strength & dexterity, and psychological well-being in individuals with Parkinson's Disease (PD). The rock climbing sessions are administered and supervised by Up ENDing Parkinson's, and are tailored to the skill level of the participant. Participants will answer questionnaires and complete physical performance tests twice, first prior to beginning the sessions and then again after the 24 sessions have been completed.

Condition or Disease Intervention/Treatment Phase
  • Other: rock climbing

Detailed Description

Parkinson's disease (PD) compromises multiple systems (neurological, musculoskeletal, cardiopulmonary, cognitive) over time, leading to functional decline. Additionally, individuals with PD may experience stressors commonly associated with chronic illness that can negatively impact psychological well-being. Exercise is commonly prescribed for individuals with PD and recently, interventions that are vigorous in nature and community- and performance-based are gaining traction (e.g., dancing, boxing, rock climbing). Despite increasing popularity, the evidence-base for these programs is still developing and far from conclusive. Recommendations are strong for: Community-based exercise, intensive aerobic and resistance training, and external cueing (Osborne et al., 2022). Rock climbing (RC) contains each of these elements and could potentially be a therapeutic intervention for people with PD. Yet little is known about the outcomes of this particular form of organized physical activity programs for this health condition. One such program is the rock climbing experiences offered by the UpENDing Parkinson's Rock Climbing (UEPRC).

The specific aims of this study are to characterize the effects of UEPRC on: 1) mobility and walking; 2) upper extremity (UE) functioning and 3) psychological and social well-being.

Participants will complete 24 rock climbing sessions tailored to their skill levels supervised by UEPRC over approximately 12 weeks.

Study Design

Study Type:
Observational
Anticipated Enrollment :
50 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Effects of Rock Climbing on Parkinson's Disease
Anticipated Study Start Date :
Jul 1, 2023
Anticipated Primary Completion Date :
May 31, 2024
Anticipated Study Completion Date :
May 31, 2024

Outcome Measures

Primary Outcome Measures

  1. Change in Community Mobility and Ambulation [Baseline and at 12 weeks]

    Test of specific tasks to be accomplished to walk forward on a level surface safely and efficiently as evidence by the Community Balance and Mobility Scale (CBMS). CBMS is scored from 0-96 with higher scores denoting better performance.

Secondary Outcome Measures

  1. Change in Agility [Baseline and at 12 weeks]

    Test of the ability to move forward, laterally, and backward on a level surface safely and efficiently as evidence by the Agility T-Test.

  2. Change in Dexterity [Baseline and at 12 weeks]

    This test assesses upper extremity dexterity by assessing the time it takes to remove 9 pegs from a tray and place in peg holes and then remove pegs and place them back in tray as measured by the 9-Hole Peg Test.

  3. Change in Reaction Time [Baseline and at 12 weeks]

    This test assesses combined cognitive and physical reaction time to initiate a movement response utilizing colored light stimuli as evidenced by using Blaze Pods.

  4. Change in Apathy [Baseline and at 12 weeks]

    This survey addresses lack of emotion, interest, concern, or recognition of goals by measuring levels of participant's interest, motivation, and engagement as evidenced by the Starkstein Apathy Scale. The Starkstein Apathy Scale scores range from 0-42 with higher scores representing greater levels of apathy.

  5. Change in Resilience [Baseline and at 12 weeks]

    This survey measures one's ability to thrive in the face of adversity as evidenced by the Connor-Davidson Resilience Scale 25 (CD-RISC-25). CD-RISC-25 scores range from 0-100 with higher scores indicating greater resilience.

  6. Change in Social Adaptation [Baseline and at 12 weeks]

    This survey measures motivation and behavior as related to work and hobbies, family and relationships, and social situations as evidenced by the Social Adaptation Self-Evaluation Scale (SAS). SAS scores range from 0-63 with higher scores representing better social adaptation.

Other Outcome Measures

  1. Change in Grip strength [Baseline and at 12 weeks]

    Measure of force production in the dominant hand using a hand-held dynamometer. The score is force output in pounds, with higher force output representing greater strength.

  2. Change in Quality of Life across Multiple Dimensions: Perception of difficulty with daily life across 8 dimensions of daily living [Baseline and at 12 weeks]

    This survey is a multidimensional survey covering mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort as evidenced by the Parkinson's Disease Questionnaire-39 (PDQ-39). PDQ-39 provides scores from 0-100 in each of the 8 domains listed and an overall Summary Index score from 0-100. Lower scores reflect better quality of life.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • at least 18 years old

  • Diagnosis of Parkinson's disease

  • Hoehn & Yahr score 1-3

  • able to speak and read in English;

  • able to ambulate at least 10 meters with no assistive device or human assistance

Exclusion Criteria:
  • neurological disease diagnosis other than PD;

  • uncontrolled cardiovascular, pulmonary, neurological, or metabolic disease which may impact the ability to exercise or in which exercise is contraindicated;

  • cognitive or psychiatric impairment precluding informed consent or ability to following instructions;

  • pregnancy;

  • inability to ambulate 10 meters without assistive device or human assistance

Contacts and Locations

Locations

Site City State Country Postal Code
1 Marymount University Arlington Virginia United States 22201

Sponsors and Collaborators

  • Marymount University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Julie Ries, Professor, Marymount University
ClinicalTrials.gov Identifier:
NCT05919771
Other Study ID Numbers:
  • 831
First Posted:
Jun 26, 2023
Last Update Posted:
Jul 3, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 3, 2023